March 2026 Quarterly Activities Report and Appendix 4C
| Stock | Noxopharm Ltd (NOX.ASX) |
|---|---|
| Release Time | 24 Apr 2026, 9:23 a.m. |
| Price Sensitive | Yes |
Noxopharm Reports March 2026 Quarterly Activities
- MoU signed with Tezcat Biosciences to deepen collaboration
- Sofra™ breakthrough science published in major medical journal
- Dr Olivier Laczka appointed as new CEO to focus on Sofra RNA program
Noxopharm Limited (ASX:NOX) has provided its Quarterly Activities Report and Appendix 4C for the period ending 31 March 2026. Key highlights include the signing of a MoU with US company Tezcat Biosciences to deepen their collaboration, the publication of a significant paper detailing the breakthrough science underlying the Sofra™ platform in the prestigious journal Nature Immunology, and the appointment of Dr Olivier Laczka as the new CEO to focus on the Sofra RNA program. The company also attended the launch of a new patient-led pain management tool in Canberra. Financially, Noxopharm had A$950k in cash at the end of the quarter, with net cash inflows from operating activities of A$848k. The company continues to explore options to secure additional capital to fund its R&D activities. Overall, the quarter saw important progress in Noxopharm's key programs and strategic partnerships.
The company continues to be vigilant with its cash resources and is exploring a range of options in relation to securing additional capital to sustain the anticipated level of R&D activities.